新辅助化疗后前哨淋巴结残留微转移患者腋窝淋巴结清扫的肿瘤学结局:OPBC-07/microNAC国际回顾性队列研究
该国际回顾性队列研究纳入1585例新辅助化疗后前哨淋巴结残留微转移(ypN1mi)的乳腺癌患者,比较行与未行腋窝淋巴结清扫(ALND)的肿瘤学结局。多因素分析中三阴性乳腺癌和省略淋巴结放疗与腋窝复发风险增加独立相关,而省略ALND未显示独立关联。
要点
- 三阴性乳腺癌和省略淋巴结放疗是腋窝复发的独立危险因素。
核心结论
- 总体结果不支持对所有接受淋巴结放疗的ypN1mi患者常规行ALND,但考虑省略ALND时应结合肿瘤生物学特征。
研究设计与样本
- OPBC-07/microNAC为国际回顾性队列研究,数据来自30个国家84个癌症中心的机构数据库。
- 研究注册号ClinicalTrials.gov NCT06529302。
临床怎么用
- 对于接受淋巴结放疗的ypN1mi患者,可考虑省略ALND,但三阴性乳腺癌患者应谨慎评估省略ALND的风险。
- 临床决策应结合肿瘤生物学特征(如三阴性状态)和是否计划行淋巴结放疗来个体化确定腋窝处理方式。
局限性
- 本研究为回顾性队列研究,存在选择偏倚和残余混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the paucity of outcome data, axillary lymph node dissection (ALND) is increasingly being omitted in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy, particularly in those with low-volume residual disease. We investigated oncological outcomes in patients with breast cancer and residual micrometastases in the sentinel lymph nodes treated with or without ALND. METHODS: OPBC-07/microNAC was a retrospective cohort study, using data obtained from the institutional databases of 84 cancer centres in 30 countries. Patients aged 18 years or older with clinical T1-4, N0-3 breast cancer at diagnosis treated with neoadjuvant chemotherapy followed by surgery between Jan 1, 2013, and May 31, 2023, who were found to have residual micrometastases (metastasis measuring >0·2 mm or >200 cells, not exceeding 2·0 mm in size) on frozen section or on final paraffin sections as determined by sentinel lymph node biopsy, targeted axillary dissection (sentinel lymph node biopsy with single or dual-tracer mapping plus image-guided localisation of the initially biopsy-proven and clipped node), or the marking axillary lymph nodes with radioactive iodine seeds (MARI) procedure were eligible for inclusion. The primary endpoint was the 5-year rate of any axillary recurrence (isolated or combined with local or distant recurrence) stratified by type of axillary surgery. Given the median follow-up, here we report 3-year rates and exploratory 5-year estimates. This study was registered with ClinicalTrials.gov, NCT06529302. FINDINGS: 1585 female patients with ypN1mi disease were analysed, of whom 804 (50·7%) underwent ALND and 781 (49·3%) did not. Of 1585 women, 238 (15·0%) self-identified as Asian, 65 (4·1%) as Black, 200 (12·6%) as Hispanic, 968 (61·1%) as White, and 114 (7·2%) as unknown race and ethnicity. 925 (58·4%) of 1585 women had cT2 tumours, 1054 (66·5%) were node positive, and 1267 (79·9%) received nodal radiotherapy. The median follow-up was 3·1 years (IQR 1·8-5·2). The 3-year rate of any axillary recurrence (isolated or combined with local or distant recurrence) for the entire cohort was 2·0% (95% CI 1·3-2·9), with no statistical difference identified by extent of axillary surgery. However, patients with triple-negative disease who did not receive ALND had significantly higher rates of any axillary recurrence than women treated with ALND (8·7% [95% CI 4·4-15·0] vs 2·4% [95% CI 0·7-6·5], p=0·018). On multivariable analysis, triple-negative breast cancer (hazard ratio 3·83 [95% CI 1·72-8·52]) and omission of nodal radiotherapy (2·62 [1·19-5·73]) but not omission of ALND (0·86 [0·37-2·00]) were independently associated with an increased risk of any axillary recurrence. INTERPRETATION: Overall, these results do not support ALND for all patients with ypN1mi on sentinel lymph node biopsy treated with nodal radiotherapy; however, tumour biology should be taken into account when considering ALND omission. FUNDING: US National Institutes of Health, National Cancer Institute.
引用
- Montagna G, Alvarado M, Myers S, et al. Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study. Lancet Oncol. 2026. PMID: 41449148. doi:10.1016/S1470-2045(25)00598-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。